Enfusion, Inc. (NYSE:ENFN) Receives Consensus Recommendation of “Reduce” from Analysts

Enfusion, Inc. (NYSE:ENFNGet Free Report) has earned an average recommendation of “Reduce” from the six research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $9.33.

A number of analysts have commented on the stock. Morgan Stanley assumed coverage on shares of Enfusion in a report on Friday, May 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Bank of America increased their price objective on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 13th. Finally, The Goldman Sachs Group downgraded shares of Enfusion from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $9.00 to $8.00 in a research note on Wednesday, February 28th.

View Our Latest Report on Enfusion

Enfusion Trading Up 0.3 %

Shares of ENFN stock opened at $9.41 on Friday. The stock’s 50-day moving average price is $9.38 and its 200-day moving average price is $9.25. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.56. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 313.67, a price-to-earnings-growth ratio of 2.20 and a beta of 0.97.

Enfusion (NYSE:ENFNGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The firm had revenue of $48.05 million during the quarter, compared to analysts’ expectations of $47.67 million. During the same quarter in the previous year, the firm posted $0.04 EPS. As a group, research analysts predict that Enfusion will post 0.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Enfusion

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank grew its position in Enfusion by 33.7% during the third quarter. Amalgamated Bank now owns 5,230 shares of the company’s stock worth $47,000 after buying an additional 1,317 shares during the period. Barclays PLC boosted its position in Enfusion by 29.0% during the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after acquiring an additional 2,430 shares during the last quarter. California State Teachers Retirement System boosted its position in Enfusion by 11.0% during the first quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock worth $333,000 after acquiring an additional 3,556 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Enfusion during the first quarter worth approximately $44,000. Finally, Swiss National Bank raised its stake in Enfusion by 17.4% during the fourth quarter. Swiss National Bank now owns 58,100 shares of the company’s stock worth $564,000 after purchasing an additional 8,600 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Company Profile

(Get Free Report

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

See Also

Analyst Recommendations for Enfusion (NYSE:ENFN)

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.